Cancer remains the second leading cause of death in the US, accounting for 25% of all
deaths nationwide. Immunotherapy techniques bolster the immune cells' ability to target …

Introduction Prognosis of patients with metastatic pancreatic ductal adenocarcinoma
(mPDAC) remains disappointing with a 5-year overall survival of only 3–5%. Compared to …

As aging and tumorigenesis are tightly interconnected biological processes, targeting their
common underlying driving pathways may induce dual‐purpose anti‐aging and anti‐cancer …

Pancreatic cancer (PC) is a lethal type of cancer for which effective therapies are limited.
Long non‑coding RNAs (lncRNAs) represent a critical type of regulator category, mediating …

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated
in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown …

The prognosis of patients with high-risk neuroblastoma remains poor, partly due to
inadequate immune recognition of the tumor. Neuroblastomas display extremely low surface …

Glycogen synthase kinase-3 (GSK-3) is an evolutionarily conserved, ubiquitously
expressed, multifunctional serine/threonine protein kinase involved in the regulation of a …

Inorganic pyrophosphatase (PPA1) encoded by PPA1 gene belongs to Soluble
Pyrophosphatases (PPase) family and is expressed widely in various tissues of Homo …

Glycogen synthase kinase-3 beta (GSK-3β) is a desired pharmacological target for cancer
treatment. Despite its role in the development of various cancers, any target directing GSK-3 …

Pancreatic cancer remains one of the most lethal malignancies, characterized by limited
therapeutic options and poor prognoses. Here, we report the development of novel dual …